Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03386214 · ClinicalTrials.gov registry record · Phase 1
Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis
A Phase 1 study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03386214 is a Phase 1 study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 8 participants.
The verdict
NCT03386214, a Phase 1 study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Based on the investigators' preclinical data, the combination of pevonedistat and ruxolitinib may provide greater clinical responses in patients with myelofibrosis compared to ruxolitinib monotherapy via inhibition of NFκB in addition to JAK-STAT signaling.
Interventions
- DRUG Ruxolitinib
- PROCEDURE Peripheral blood draw
- DRUG Pevonedistat
- PROCEDURE Skin biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-04-23 |
| Est. Completion | 2021-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03386214
The ClinicalTrials.gov registry entry for NCT03386214 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ruxolitinib is the first listed.
NCT03386214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03386214 about?
NCT03386214 is a clinical study titled "Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis". Based on the investigators' preclinical data, the combination of pevonedistat and ruxolitinib may provide greater clinical responses in patients with myelofibrosis compared to ruxolitinib monotherapy via inhibition of NFκB in addition to JAK-STAT signaling.
What is the current status of trial NCT03386214?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-04-23. Estimated completion is 2021-10-04.
What interventions are being tested in trial NCT03386214?
The interventions under investigation include: Ruxolitinib (DRUG), Peripheral blood draw (PROCEDURE), Pevonedistat (DRUG), Skin biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT03386214?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.